TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
8/11/22 20:53 | 8/9/22 | EPZM | Epizyme, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Agarwal Shefali | MA | H | See Rema | M.d | 695 | 1.39 | 0 | 500 | 286 | D | |||||||||||||||
6/8/22 16:03 | 6/7/22 | FATE | Fate Therapeutics Inc | Health | BioPrd | Biological Products, (No Diag | Agarwal Shefali | CA | D | S | -18 | 21.89 | 0 | -1 | -31 | 2 | D | ||||||||||||||||
6/8/22 16:01 | 6/3/22 | FATE | Fate Therapeutics Inc | Health | BioPrd | Biological Products, (No Diag | Agarwal Shefali | CA | D | S.a | 0 | 0.00 | 0 | 0 | 0 | 3 | D | ||||||||||||||||
6/6/22 16:40 | 6/3/22 | FATE | Fate Therapeutics Inc | Health | BioPrd | Biological Products, (No Diag | Agarwal Shefali | CA | D | S | -18 | 22.80 | 0 | -1 | -30 | 2 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |